Скачать или смотреть Enoblituzumab Unveiling the Role of Anti-B7-H3 in Cancer Research

https://www.assaygenie.com/anti-b7-h3...

Main Themes:

Enoblituzumab as an Immunotherapeutic Agent: Enoblituzumab is a monoclonal antibody targeting the B7-H3 protein, a key player in immune evasion mechanisms employed by various cancer cells.
B7-H3 and Immune Evasion: B7-H3, overexpressed in cancers like prostate, melanoma, and lung cancer, suppresses T-cell activation, allowing tumors to evade immune surveillance. Enoblituzumab counteracts this by binding to B7-H3, reactivating the immune response.
Mechanism of Action: Enoblituzumab specifically binds to B7-H3 on tumor cells, blocking its immune-suppressive function. This reactivates T-cells and enhances their ability to target and destroy cancer cells.
Clinical Applications: Enoblituzumab is being investigated for the treatment of various cancers, including:
Prostate cancer
Sarcoma
Ovarian cancer
Combination Therapies: Research is exploring the use of Enoblituzumab in combination with other immunotherapies, such as pembrolizumab (targeting the PD-1 receptor), to enhance treatment efficacy.
Enoblituzumab Biosimilar: A cost-effective biosimilar of Enoblituzumab is available for research purposes, enabling large-scale studies on anti-B7-H3 therapies.

Important Ideas/Facts:

Quote: "Enoblituzumab is an innovative immunotherapeutic agent designed to target B7-H3, a protein that is often overexpressed on the surface of various tumor cells."
Specificity: Enoblituzumab selectively targets tumor cells overexpressing B7-H3, potentially leading to more effective treatments with fewer side effects.
Promising Results: Early-stage clinical trials show promising results for Enoblituzumab's safety and efficacy in treating various cancers.
Ongoing Research: Further research is needed to fully understand Enoblituzumab's potential, particularly in combination therapies and its application in other cancer types.
Research Tool: The availability of an Enoblituzumab biosimilar is valuable for researchers studying anti-B7-H3 therapies.